Precision BioSciences, Inc. (DTIL)
Nasdaq · Healthcare · Biotechnology
$6.310.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $174M
- 52-week range
- $3.53 – $9.62
- 52-week change
- +11.09%
- EPS (trailing)
- −$1.35
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $34.3M (−50.12%)
- Net income
- −$45.7M
- Operating margin
- −152.2%
- Diluted EPS
- −$3.56
- Free cash flow
- −$65.9M
From the company’s annual report on SEC EDGAR.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Headquarters: Durham, United States · 67 employees · precisionbiosciences.com